Pharmafile Logo
Pharmafocus logo
Advanced Search

elotuzumab

Showing 4 posts of 4 posts found.

Multiple myeloma treatment from BMS and AbbVie scores EU approval

May 12, 2016
Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma

Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …

News
Empliciti logo

FDA approves BMS and AbbVie’s Empliciti for multiple myeloma

December 1, 2015
Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma

The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …

News

Priority review for Novartis myeloma drug

November 26, 2014
Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac

Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …

News
bms_close_logo

BMS and AbbVie get FDA lift

May 21, 2014
Research and Development, Sales and Marketing AbbVie, BMS, FDA, elotuzumab, multiple, myeloma

Bristol-Myers Squibb and AbbVie are celebrating after receiving breakthrough designation status from the US regulator for their investigational medicine elotuzumab …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024